Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Association of Labor Epidural Analgesia With Autism Spectrum Disorder in Children

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years

    Research output: Contribution to journalLetterResearchpeer-review

  3. Prevalence of Bicuspid Aortic Valve and Associated Aortopathy in Newborns in Copenhagen, Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Readmission and Death After Initial Hospital Discharge Among Patients With COVID-19 in a Large Multihospital System

    Research output: Contribution to journalLetterResearchpeer-review

  5. Assessing Progress in Health Care Quality Through the Lens of COVID-19

    Research output: Contribution to journalComment/debateResearchpeer-review

  1. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Improved Survival of Children, Adolescents, and Young Adults With Head and Neck Soft Tissue Sarcomas in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Patient and Tumour Characteristics of Adult Head and Neck Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis

    Research output: Contribution to journalReviewResearchpeer-review

  • ANNOUNCE Investigators
View graph of relations

Importance: Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxorubicin alone.

Objective: To determine the efficacy of doxorubicin plus olaratumab in patients with advanced/metastatic STS.

Design, Setting, and Participants: ANNOUNCE was a confirmatory, phase 3, double-blind, randomized trial conducted at 110 sites in 25 countries from September 2015 to December 2018; the final date of follow-up was December 5, 2018. Eligible patients were anthracycline-naive adults with unresectable locally advanced or metastatic STS, an Eastern Cooperative Oncology Group performance status of 0 to 1, and cardiac ejection fraction of 50% or greater.

Interventions: Patients were randomized 1:1 to receive doxorubicin, 75 mg/m2 (day 1), combined with olaratumab (n = 258), 20 mg/kg in cycle 1 and 15 mg/kg in subsequent cycles, or placebo (n = 251) on days 1 and 8 for up to 8 21-day cycles, followed by olaratumab/placebo monotherapy.

Main Outcomes and Measures: Dual primary end points were overall survival with doxorubicin plus olaratumab vs doxorubicin plus placebo in total STS and leiomyosarcoma (LMS) populations.

Results: Among the 509 patients randomized (mean age, 56.9 years; 58.2% women; 46.0% with LMS), all were included in the primary analysis and had a median length of follow-up of 31 months. No statistically significant difference in overall survival was observed between the doxorubicin plus olaratumab group vs the doxorubicin plus placebo group in either population (total STS: hazard ratio, 1.05 [95% CI, 0.84-1.30], P = .69, median overall survival, 20.4 months vs 19.7 months; LMS: hazard ratio, 0.95 [95% CI, 0.69-1.31], P = .76, median overall survival, 21.6 months vs 21.9 months). Adverse events of grade 3 or greater reported in 15% or more of total patients with STS were neutropenia (46.3% vs 49.0%), leukopenia (23.3% vs 23.7%), and febrile neutropenia (17.5% vs 16.5%).

Conclusions and Relevance: In this phase 3 clinical trial of patients with advanced STS, treatment with doxorubicin plus olaratumab vs doxorubicin plus placebo resulted in no significant difference in overall survival. The findings did not confirm the overall survival benefit observed in the phase 2 trial.

Trial Registration: ClinicalTrials.gov Identifier: NCT02451943.

Original languageEnglish
JournalJAMA - Journal of the American Medical Association
Volume323
Issue number13
Pages (from-to)1266-1276
Number of pages11
ISSN0002-9955
DOIs
Publication statusPublished - 7 Apr 2020

    Research areas

  • Adult, Aged, Aged, 80 and over, Antibiotics, Antineoplastic/administration & dosage, Antibodies, Monoclonal/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Double-Blind Method, Doxorubicin/administration & dosage, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Placebos/therapeutic use, Proportional Hazards Models, Sarcoma/drug therapy, Survival Analysis, Young Adult

ID: 61915522